Hiroaki Wakimoto

Oct 31, 2023 | frontiersin.org | Cellworks Group |David Eisenstat |Hiroaki Wakimoto |Rebecca Brown

BackgroundLeptomeningeal spread of glioblastoma (LM-GBM) is a life-threatening disease renowned for dire neurological sequelae and short median survival of 1.6 to 3.8 months (1). Though responses to chemotherapy are documented and generally favor a disposition of intervention, single agents accomplish relatively little against complex diseases like LM-GBM.